The two recommended NRTI options for treatment of naïve patients with wild-type HIV alone are abacavir/3TC and tenofovir/FTC [124]. Although 3TC is a potent www.selleckchem.com/products/GDC-0449.html anti-HBV agent [131], monotherapy is associated

with a high likelihood of HBV resistance in coinfected persons (M204 V develops at a rate of 25%/year) and hence therapy with this drug, or FTC, without a second anti-HBV active drug is not recommended [132,133]. 3TC/FTC-resistant strains will normally respond to tenofovir [118–123,134–137] Tenofovir is effective at suppressing HBV DNA and may induce HBeAg seroconversion although, as for other antivirals in coinfection, this may be less likely than in an HIV-negative person [127,134–136]. Resistance is

rare and combination with 3TC or FTC has been demonstrated to be effective at suppressing HBV DNA and may induce HBeAg seroconversion. Combining 3TC/FTC with tenofovir may reduce the risk of breakthrough [137]. If renal toxicity precludes the use of tenofovir, entecavir is an option that can be used along with a fully active antiretroviral regimen [137]. If AC220 clinical trial genotypic HIV resistance to tenofovir and/or 3TC/FTC is present or develops, but HBV DNA suppression is maintained, tenofovir and 3TC/FTC should be continued in addition to an effective new antiretroviral regimen. The presence of mutations conferring 3TC resistance affects the fitness of both viruses which potentially slows down HBV progression and therefore continuing this drug should be considered [131]. ART may lead to an immune reconstitution flare when commenced, and a viral escape inflammatory flare if drugs with medroxyprogesterone anti-HBV activity are stopped, both of which may be severe, particularly in persons with cirrhosis [138,139]. 4.3.2.3 Recommendations for patients with a CD4≥500 cells/μL • No HBV therapy is recommended for patients who are HBsAg and HBV DNA negative but HBcAb positive (I). 4.3.2.4 Recommendations for patients with a CD4<500 cells/μL • Patients

with HBV coinfection who have a CD4 count of <500 cells/μL should commence HAART (II). The only exception to this may be the patient with a CD4 count of 350–500 cells/μL, an HBV DNA level of <2000 IU/mL, a normal ALT and no evidence of fibrosis or hepatic inflammation: in this situation, close monitoring is essential. 4.3.2.5 Goals of therapy. As in HBV monoinfection, the long-term goal is to prevent cirrhosis and primary hepatoma by sustained suppression of viral replication to the lowest possible level [140]. Seroconversion from HBeAg positive to HBeAg negative and normalization of ALT are endpoints that indicate success of therapy in monoinfected patients and allow consideration for discontinuation of treatment.